19 January 2023 – US Review on prevention of surgical site infection endorsing value of nasal decolonisation

US expert publishes review on the prevention of surgical site infection (SSI), endorsing the value of nasal decolonisation of S. aureus/MRSA.  Dr Deverick Anderson, Professor of Medicine at Duke University, USA & Director of the Duke Center for Antimicrobial Stewardship and Infection Prevention, and colleagues published a paper entitled ‘Surgical Site Infection Prevention: A Review’ in JAMA (Journal of the American Medical Association) based on a large scientific literature search covering 2016 to 2022.  Click here for review.

In the review Dr Anderson underlines that SSIs are predominantly caused by S. aureus/MRSA with US hospitals suffering up to 500,000 such SSIs a year at a cost of $10 billion to the US healthcare system.  He reviews and comments on the latest data which supports nasal decolonisation of S. aureus/MRSA in patients undergoing surgery as a valuable SSI preventive intervention, stating that a rapid decolonisation immediately ahead of surgery is most desirable and effective.

Destiny Pharma’s lead candidate, XF-73, is a novel drug targeting nasal decolonisation heading towards P3 studies.

A podcast is available where Dr Anderson discusses his findings in great detail.  Click here for podcast.